Сахарный диабет и интервенционная кардиология: если к правде святой

1. Bonello L, Sbragia P, Amabile P et al. Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention. Heart 2007; 93: 703–7.
2. Romano M, Spineli R et al. Trimetazidine in patients with previous myocardial revascularization and left ventricular dysfunction. An exercise stress testing and radionuclide study. It J Practice Cardiol 2003; 0: 29–36.
3. Lech Polonsky, Iwona Dec et al. Trimetazidine Limits the Effects of Myocardial Ischemia During Percutaneous Coronary Angioplasty. Current Med Res Opin 2002; 18 (7): 389–96.
4. Napoli, Pericle Di; Giovanni, Paolo Di; Gaeta, Marta Assunta et al. Trimetazidine and Reduction in Mortality and Hospitalization in Patients With Ischemic Dilated Cardiomyopathy: A Post Hoc Analysis of the Villa Pini D'Abruzzo Trimetazidine Trial. J Cardiovasc Pharmacol 2007; 50 (5): 585–9.
5. Belardinelli, Romualdo; Cianci, Giovanni; Gigli, Mirko et al. Effects of Trimetazidine on Myocardial Perfusion and Left Ventricular Systolic Function in Type 2 Diabetic Patients With Ischemic Cardiomyopathy. J Cardiovasc Pharmacol 2008; 51 (6): 611–5.
6. Rosano CMC, Vitale C, Sposato В et al. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study Cardiovascular Diabetol 2003; 2: 16.
7. Лопатин Ю.М., Дронова Е.П. Клинико-фармакоэкономические аспекты применения триметазидина модифицированного высвобождения у больных ишемической болезнью сердца, подвергнутых коронарному шунтированию. Кардиология. 2009; 2: 15–21.
8. Labrou A, Yiannoglou G et al. The role of trimetazidine at PTC A procedure: dose trimetazidine minimize myocardial damage during PTC A? Eur Heart J 2005; 26 (Abstract Supplement): 40.
9. Labrou A, Giannoglou G et al. Trimetazidine Administration Minimizes Myocradial Damage and Imroves Left Ventricular Function after Percutaneous Coronary Intervention. Am J Cardiovasc Drugs 2007; 7 (2): 143–50.
10. Ruzyllo W, Szwed H, Sadowski Z et al. Efficacy of trimetazidine in patients with recurrent angina: a subgroup analysis of the TRIMPOL II study. Cur Med Res Opin 2004; 20 (9): 1447–54.
11. The BARI Investigators. Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. J Am Coll Cardiol 2000; 35: 1122–9.
12. Norell MS, Perrins EJ, Meier B et al. Essential interventional cardiology. 2nd Edition. Sunders Elsevier, P. 560.
13. Васюк Ю.А., Ющук E.H., Школьник Е.Л. и др. Возможности миокардиальной цитопротекции в комплексном лечение больных с хронической сердечной недостаточностью. Кардиология. 2006; 8: 48–56.
14. Serruys PW, Morice MC, Kappetein АР et al. Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease. N Engl J Med 2009; 360: 961.
15. Authors/Task Force Members, Lars Ryden, Eberhard Standl, Malgorzata Bartnik, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88–136.
16. Albertal M, Regar E, Van Langenhove G et al. Flow velocity and predictors of a suboptimal coronary flow velocity reserve after coronary balloon angioplasty. Eur Heart J 2002; 23: 133–8.
17. Detre KM, Guo P, Holubkov R et al. Coronary Revascularization in Diabetic Patients: A Comparison of the Randomized and Observational Components of the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1999; 99: 633–40.
18. Roffi M, Chew DP, Mukherjee D et al. Topol Platelet Glycoprotein Ilb/IIIa Inhibitors Reduce Mortality in Diabetic Patients With Non-ST-Segment-Elevation Acute Coronary Syndromes. Circulation 2001; 104: 2767–71.
19. Braunwald E, Kloner RA. The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation 1982; 66: 1146–9.
20. Bolli R. Myocardial 'stunning' in man. Circulation 1992; 86: 1671–91.
21. Marban E, Kitakaze M, Koretsune Y et al. Quantification of [Ca2+]i in perfused hearts. Critical evaluation of the 5F-BAPTA and nuclear magnetic resonance method as applied to the study of ischemia and reperfusion. Circ Res 1990; 66: 1255–67.
22. Gao WD, Atar Y, Liu NG et al. Role of troponin I proteolysis in the pathogenesis of stunned myocardium. Circ Res 1997; 80: 393–9.
23. Grinwald PM. Calcium uptake during postischemic reperfusion in the isolated rat heart: influence of extracellular sodium. J Mol Cardiol 1982; 14: 359–65.
24. Gao WD, Atar D, Backx PH, Marban E. Relationship Between Intracellular Calcium and Contractile Force in Stunned Myocardium: Direct Evidence for Decreased Myofilament Ca2+ Responsiveness and Altered Diastolic Function in Intact Ventricular Muscle. Circ Res 1995; 76: 1036–48.
25. McDonald KS, Mammen PPA, Moss RL, Miller WP. Decreased myoflament Ca++ sensitivity alone may not account for the depressed contractile state of stunned myocardium (Abstract). Circulation 1993; 88 (Suppl. 1): 1–130.
26. Gao WD, Liu Y, Mellgren R, Marban E. Intrinsic Myofllament Alterations Underlying the Decreased Contractility of Stunned Myocardium: A Consequence of Ca2+-Dependent Proteolysis? Circ Res 1996; 78: 455–65.